Sildenafil citrate in a donation after circulatory death experimental model of renal ischemia-reperfusion injury

Transplantation

Volumn 98, Issue 6, 2014, Pages 612-617

  Hosgood, Sarah A ^a   Randle, Lucy V ^b   Patel, Meeta ^a   Watson, Christopher J ^b   Bradley, John A ^b   Nicholson, Michael L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Ischemia reperfusion injury; Kidney; Sildenafil citrate

Indexed keywords

BIOLOGICAL MARKER; CYCLIC GMP; SILDENAFIL; CREATINE; ENDOTHELIN 1; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD OXYGENATION; COLD ISCHEMIA; CONTROLLED STUDY; DEATH; DRUG EFFECT; DRUG MECHANISM; EX VIVO STUDY; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; NONHUMAN; PIG; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; ANIMAL; AREA UNDER THE CURVE; BLOOD; DRUG EFFECTS; ISCHEMIA; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PROCEDURES; SWINE; TIME;

ANIMALS; AREA UNDER CURVE; COLD ISCHEMIA; CREATINE; CYCLIC GMP; ENDOTHELIN-1; KIDNEY; KIDNEY TRANSPLANTATION; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RENAL CIRCULATION; REPERFUSION INJURY; SULFONES; SWINE; TIME FACTORS; WARM ISCHEMIA;

EID: 84922481259     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000283     Document Type: Article

References (33)

1. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121: 4210.
2. Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
3. Siedlecki A, IrishW, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant 2011; 11: 2279.
4. Bonventre JV.Mediators of ischemic renal injury. Annu Rev Med 1988; 39: 531.
5. Francis SH, Corbin JD. Phosphodiesterase-5 inhibition: The molecular biology of erectile function and dysfunction. Urol Clin North Am 2005; 32: 419.
6. Madden B, Crerar-Gilbert A. Pulmonary hypertension and sildenafil. Br J Anaesth 2005; 95: 562.
7. Oruc O, Inci K, Aki FT, et al. Sildenafil attenuates renal ischemia reperfusion injury by decreasing leukocyte infiltration. Acta Histochem 2010; 112: 337.
8. Choi DE, Jeong JY, Lim BJ, et al. Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol 2009; 297: F362.
9. Gori T, Sicuro S, Dragoni S, et al. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005; 111: 742.
10. Medeiros PJ, Villarim Neto A, Lima FP, et al. Effect of sildenafil in renal ischemia/reperfusion injury in rats. Acta Cir Bras 2010; 25: 490.
11. Kukreja RC, Ockaili R, Salloum F, et al. Cardioprotection with phosphodiesterase-5 inhibitionVa novel preconditioning strategy. J Mol Cell Cardiol 2004; 36: 165.
12. Lledo-Garcia E, Subira-Rios D, Rodriguez-Martinez D, et al. Sildenafil as a protecting drug for warm ischemic kidney transplants: experimental results. J Urol 2009; 182: 1222.
13. Patel NN, Lin H, Toth T, et al. Phosphodiesterase-5 inhibition prevents postcardiopulmonary bypass acute kidney injury in swine. Ann Thorac Surg 2011; 92: 2168.
14. Hosgood SA, Bagul A, Yang B, et al. The relative effects of warm and cold ischemic injury in an experimental model of nonheartbeating donor kidneys. Transplantation 2008; 85: 88.
15. Yates PJ, Hosgood SA, Nicholson ML. A biphasic response to nitric oxide donation in an ex vivo model of donation after cardiac death renal transplantation. J Surg Res 2012; 175: 316.
16. Schinner E, Schramm A, Kees F, et al. The cyclic GMP-dependent protein kinase I suppresses kidney fibrosis. Kidney Int 2013; 84: 1198.
17. Salloum FN, Takenoshita Y, Ockaili RA, et al. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 2007; 42: 453.
18. Mennander AA, Vuohelainen V, Aanismaa RS, et al. Sildenafil after cardiac arrest and infarction; an experimental rat model. Scand Cardiovasc J 2013; 47: 58.
19. Das A, Salloum FN, Xi L, et al. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2009; 296: H1236.
20. Fernandes MA, Marques RJ, Vicente JA, et al. Sildenafil citrate concentrations not affecting oxidative phosphorylation depress H2O2 generation by rat heart mitochondria. Mol Cell Biochem 2008; 309: 77.
21. Kucuk A, Yucel M, Erkasap N, et al. The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats. Mol Biol Rep 2012; 39: 9775.
22. Elrod JW, Greer JJ, Lefer DJ. Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol 2007; 292: H342.
23. Kyriazis I, Kagadis GC, Kallidonis P, et al. PDE5 inhibition against acute renal ischemia reperfusion injury in rats: does vardenafil offer protection? World J Urol 2012; 31: 597.
24. Botha P, MacGowan GA, Dark JH. Sildenafil citrate augments myocardial protection in heart transplantation. Transplantation 2010; 89: 169.
25. Korom S, Hillinger S, Cardell M, et al. Sildenafil extends survival and graft function in a large animal lung transplantation model. Eur J Cardiothorac Surg 2006; 29: 288.
26. Pizanis N, Milekhin V, Tsagakis K, et al. PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation. Eur J Cardiothorac Surg 2007; 32: 42.
27. du Toit EF, Rossouw E, Salie R, et al. Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drugs Ther 2005; 19: 23.
28. Salloum FN, Ockaili RA,Wittkamp M, et al. Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. J Mol Cell Cardiol 2006; 40: 405.
29. Sohotnik R, Nativ O, Abbasi A, et al. Phosphodiesterase-5 inhibition attenuates early renal ischemia-reperfusion-induced acute kidney injury: assessment by quantitative measurement of urinary NGAL and KIM-1. Am J Physiol Renal Physiol 2013; 304: F1099.
30. Faddegon S, Best SL, Olweny EO, et al. Tadalafil for prevention of renal dysfunction secondary to renal ischemia. Can J Urol 2012; 19: 6274.
31. Wang Y, Kramer S, Loof T, et al. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am J Physiol Renal Physiol 2006; 290: F167.
32. Hosgood SA, Yang B, Bagul A, et al. A comparison of hypothermic machine perfusion versus static cold storage in an experimental model of renal ischemia reperfusion injury. Transplantation 2010; 89: 830.
33. Frei U, Harms A, Bakovic-Alt R, et al. Calcium channel blockers for kidney protection. J Cardiovasc Pharmacol 1990; 16(Suppl 6): S11.